Valuation: Mymetics Corp

Market Cap 4L 4L 4L 3L 6L 4.23Cr 6L 42.29L 16.63L 2.07Cr 16.48L 16.12L 7.12Cr P/E 2021
-1.86x
P/E 2022 -1.77x
Enterprise Value 7.21Cr 6.3Cr 5.82Cr 5.36Cr 10Cr 694.55Cr 10Cr 70Cr 27Cr 340.16Cr 27Cr 26Cr 1.17TCr EV / Sales 2021
177x
EV / Sales 2022 78x
Free-Float
99.88%
Yield 2021 *
-
Yield 2022 -
Manager TitleAgeSince
Chief Executive Officer 58 19/11/2012
Change 5-day change 1-year change 3-year change Capi.($)
-11.43%+44.21% - - 45
+0.24%-1.54%+52.85%+71.85% 5.38TCr
-7.17%-4.39%+42.72%+73.32% 5.21TCr
+0.80%-6.31%+5.62%+417.78% 2.35TCr
-0.09%-0.01%-16.85%-15.41% 2.31TCr
-5.95%-2.58%+29.53%-9.47% 1.94TCr
-1.14%+0.03%+31.67%-30.65% 1.76TCr
-5.16%-7.00%+168.44%+314.96% 1.52TCr
-6.91%-5.83%+25.17%+644.30% 1.48TCr
+0.43%-1.03%+25.75%+189.74% 1.41TCr
Average -3.64%-2.62%+40.54%+184.05% 2.6TCr
Weighted average by Cap. -2.80%-2.36%+39.55%+143.13%

Financials

2021 2022
Net sales 4L 4L 3L 3L 6L 4.14Cr 6L 41.45L 16.3L 2.03Cr 16.15L 15.79L 6.98Cr 10.28L 9L 8L 8L 14.4L 9.9Cr 14.72L 99.09L 38.97L 4.85Cr 38.61L 37.76L 17Cr
Net income -47.3L -41.34L -38.14L -35.16L -66.27L -46Cr -67.74L -4.56Cr -1.79Cr -22Cr -1.78Cr -1.74Cr -77Cr -48.05L -41.99L -38.75L -35.72L -67.32L -46Cr -68.81L -4.63Cr -1.82Cr -23Cr -1.8Cr -1.76Cr -78Cr
Net Debt 6.71Cr 5.86Cr 5.41Cr 4.99Cr 9.4Cr 646.18Cr 9.61Cr 65Cr 25Cr 316.47Cr 25Cr 25Cr 1.09TCr 7.17Cr 6.26Cr 5.78Cr 5.33Cr 10Cr 690.33Cr 10Cr 69Cr 27Cr 338.09Cr 27Cr 26Cr 1.16TCr
Logo Mymetics Corp
Mymetics Corporation is a vaccine company. The Company is focused on developing vaccines for infectious diseases. The Company has over five vaccine candidates in its pipeline: human immunodeficiency virus type 1 (HIV-1)/acquired immune deficiency syndrome (AIDS), intra nasal Influenza, Malaria, Herpes Simplex Virus (HSV) and the Respiratory Syncitial Virus (RSV) vaccine. Its technology utilizes virosomes, lipid-based carriers containing functional fusion viral proteins and natural membrane proteins, in combination with rationally designed antigens. Its prophylactic HIV-1 vaccine candidate is constituted of virosomes linked to conserved antigens derived from the HIV-1 glycoprotein 41 (gp41) proteins from the clade B. The RSV vaccine consists of the reconstituted membrane of RSV containing the native viral proteins. The HSV vaccine candidate consists of the reconstituted membrane of HSV-1 or HSV-2. The intranasal influenza vaccine includes the reconstituted membrane of influenza virus.
Employees
-